KR101396842B1 - Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same - Google Patents
Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same Download PDFInfo
- Publication number
- KR101396842B1 KR101396842B1 KR1020120005809A KR20120005809A KR101396842B1 KR 101396842 B1 KR101396842 B1 KR 101396842B1 KR 1020120005809 A KR1020120005809 A KR 1020120005809A KR 20120005809 A KR20120005809 A KR 20120005809A KR 101396842 B1 KR101396842 B1 KR 101396842B1
- Authority
- KR
- South Korea
- Prior art keywords
- omija
- fermented
- extract
- omiza
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 12
- 238000000855 fermentation Methods 0.000 title claims description 34
- 230000004151 fermentation Effects 0.000 title claims description 34
- 240000006079 Schisandra chinensis Species 0.000 title 1
- 235000008422 Schisandra chinensis Nutrition 0.000 title 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 64
- 239000000284 extract Substances 0.000 claims abstract description 43
- 241001400472 Omiza Species 0.000 claims abstract description 30
- 238000004519 manufacturing process Methods 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 230000001900 immune effect Effects 0.000 claims abstract description 11
- 230000036039 immunity Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 12
- 229940041514 candida albicans extract Drugs 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 239000012138 yeast extract Substances 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 238000003809 water extraction Methods 0.000 claims description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002261 Corn starch Polymers 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- 239000005715 Fructose Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 4
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 4
- 239000008120 corn starch Substances 0.000 claims description 4
- 238000003808 methanol extraction Methods 0.000 claims description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- -1 malt extract Substances 0.000 claims description 2
- 235000010333 potassium nitrate Nutrition 0.000 claims description 2
- 239000004323 potassium nitrate Substances 0.000 claims description 2
- 229940001941 soy protein Drugs 0.000 claims description 2
- 239000012137 tryptone Substances 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 76
- 241000894006 Bacteria Species 0.000 abstract description 41
- 239000004310 lactic acid Substances 0.000 abstract description 38
- 235000014655 lactic acid Nutrition 0.000 abstract description 38
- 230000000845 anti-microbial effect Effects 0.000 abstract description 32
- 239000003242 anti bacterial agent Substances 0.000 abstract description 8
- 229940088710 antibiotic agent Drugs 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 241001465754 Metazoa Species 0.000 abstract description 6
- 230000002519 immonomodulatory effect Effects 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000035790 physiological processes and functions Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 230000003308 immunostimulating effect Effects 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000009897 systematic effect Effects 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 5
- 235000021053 average weight gain Nutrition 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000021107 fermented food Nutrition 0.000 description 4
- 210000004211 gastric acid Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 235000015067 sauces Nutrition 0.000 description 4
- 241000588919 Citrobacter freundii Species 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000588697 Enterobacter cloacae Species 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241000607762 Shigella flexneri Species 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 241000191963 Staphylococcus epidermidis Species 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000012970 cakes Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000013409 condiments Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical group CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002828 disc diffusion antibiotic sensitivity testing Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000015143 herbs and spices Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000011392 neighbor-joining method Methods 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Fodder In General (AREA)
Abstract
본 발명은 오미자 추출물을 유산균으로 발효시킨 오미자 발효물, 그 제조방법 및 이를 함유하는 항균 및 면역 증강용 조성물에 관한 것이다. 본 발명에 따른 오미자 발효물은 동물 사료 조성물뿐만 아니라, 식품 조성물이나 약학 조성물 등의 다양한 분야에 적용되어 체내 흡수율 및 다양한 생리 작용의 상승 효과를 통하여 우수한 면역 증강 효능 및 항균 효능을 발휘함으로써 질병을 효율적으로 예방하고, 면역력 증진에 기여할 수 있다. 또한, 본 발명에 따른 오미자 발효물을 포함하는 항균 및 면역 증강 조성물은 독성이나 내성 문제를 일으키지 않는 생약 발효 조성물로 안전성이 확보되어 있으므로, 기존 항생제의 대체 물질로써 적용될 수 있다.The present invention relates to an Omija fermented product obtained by fermenting an Omija extract with a lactic acid bacterium, a method for producing the same, and an antibacterial and immunological enhancing composition containing the same. The fermented Omiza according to the present invention is applied not only to animal feed composition but also to various fields such as food composition and pharmaceutical composition, and exhibits excellent immunity enhancing effect and antibacterial effect through synergistic effect of absorption rate and various physiological functions in the body, , And can contribute to enhancement of immunity. In addition, the antimicrobial and immunomodulating composition containing the fermented product according to the present invention can be applied as a substitute for conventional antibiotics because it is a safe fermented herbal composition which does not cause toxicity or resistance problems.
Description
본 발명은 오미자의 발효물에 관한 것으로서, 더욱 상세하게는 유산균을 이용한 오미자 발효물 및 이를 포함하는 항균 또는 면역 증강 조성물에 관한 것이다.
The present invention relates to a fermented product of Omija, and more particularly to a fermented product of Omija using a lactic acid bacterium and an antibacterial or immunomodulating composition containing the same.
의약 및 축산업 분야에서 항생제 오남용으로 인한 항생제 내성균의 급격한 증가는 사람이나 가축에 심각한 문제를 야기하고 있다. 이에 따라, 국내에서는 2011년 7월 1일부터 배합 사료 내 항생제 첨가가 전면적으로 금지되는 등 강력한 규제가 이어지고 있다. 그러나, 항생제를 사용하지 않을 경우, 질병에 그대로 노출되게 되어 폐사율 급증이나 성적 부진 등의 부작용이 발생할 수 있어, 항생제 대체 물질의 개발이 시급히 요구되는 실정이다.The rapid increase in antibiotic-resistant bacteria caused by abuse of antibiotics in the medicinal and livestock industries is causing serious problems for people and livestock. As a result, strong regulation has been continuing in Korea since July 1, 2011, as the addition of antibiotics in the diets is totally prohibited. However, if antibiotics are not used, they will be exposed to the disease, and side effects such as a rapid increase in mortality rate and poor sexuality may occur. Therefore, development of a substitute for antibiotics is urgently required.
항생제 대체 물질의 하나로서 장내 미생물의 균총을 개선하여 숙주 동물에게 유익한 작용을 하는 미생물제인 생균제가 이용되고 있다. 이러한 생균제는 각종 질병에 대한 면역력을 증가시키고, 설사 발생을 감소시키며, 혈청 내 콜레스테롤 함량 감소 및 백혈구에 의한 식균 작용을 증강시키는 것으로 알려져 있으며, 장내에서 다른 유해성 미생물의 성장을 억제하고, 섭취한 사료의 소화 흡수를 도와주는 장점을 가지고 있다. 그러나, 동물의 소화관 내에서 이러한 효능을 발휘하기 위해서는 장관 내에 성공적으로 정착해야 하는데 이에 대한 명확한 증거가 불명확하고, 따라서, 지속적인 효과를 위하여 연속적으로 투여하여야 한다는 문제가 있다. 또한, 기존의 항생제보다는 그 효능이 떨어지며, 즉각적으로 효능을 볼 수 없다는 단점을 가지고 있다.As a substitute for antibiotics, a probiotic agent, which is a microorganism that has beneficial effects on a host animal by improving intestinal microflora, has been used. These prophylactic agents are known to increase immunity against various diseases, reduce diarrhea occurrence, decrease cholesterol content in serum, and enhance phagocytosis caused by leukocytes. In addition, they inhibit the growth of other harmful microorganisms in the intestines, And it has the advantage of helping digestion and absorption. However, in order to exert such an effect in the digestive tract of an animal, there is a problem that clear evidence for this must be successfully established in the intestinal tract, and therefore, continuous administration is required for continuous effect. In addition, it has a disadvantage that its efficacy is lower than that of conventional antibiotics, and its efficacy can not be seen immediately.
이에 대하여, 한방 생약 등 식물 추출물은 오랜 역사를 지닌 우리나라의 전통 의약으로 인체 감염성 질환의 치료에 효율적으로 사용되어 왔으며, 임상적으로 이미 안전성이 확보된 소재이다. 또한, 즉각적인 효과를 나타낸다는 점에서 높은 장점을 가지고 있다. 그러나, 현재 식물에서 추출한 항생제 대체 물질로써는 사포닌, 허브, 향신료 추출물 등이 일부 사용되고 있을 뿐이며, 체계적이고 과학적인 연구 결과가 미흡한 실정이다. 또한, 생약 특성상 보관상의 문제점이 보고되고 있으며, 쓴 맛이나 아린 맛 등으로 기호성이 떨어진다는 단점도 있다.On the other hand, plant extracts such as herbal medicine have long been used as traditional medicines in Korea for effectively treating human infectious diseases and have been clinically secured. In addition, it has a high advantage in that it exhibits an immediate effect. However, saponin, herbs and spice extracts are only used as antibiotic substitutes extracted from plants at present, and systematic and scientific research results are insufficient. In addition, there are disadvantages such as storage problems due to herbal medicine properties, poor palatability due to bitter taste, aring taste, and the like.
한편, 오미자는 오미자(Schisandra chinensis)의 열매를 말린 약재이며, 동의보감에는 '오미자는 폐와 신장을 보하고, 피곤, 목마름, 번열, 해소 등을 낫게 한다'라고 기록되어 있다. 오미자의 주요 약리 성분은 시잔드린, 고미신 등과 같은 리그닌 화합물로 자양, 강장에 효능이 있으며, 두뇌 회전 촉진, 중추 신경의 기능 강화, 혈액 순환 개선, 만성 간염 치료, 정력 강화, 기침 해소, 이질, 설사 등에 효과가 있다. 또한, 오미자 추출물은 다양한 병원성 미생물에 대한 항균 효과가 있다고 밝혀졌으며, 장내 세균총 개선 및 장관 염증 억제 효과도 입증되어 있다.On the other hand, it is recorded that Schizandra chinensis is dried and the fruit of Schizandra chinensis is dried and it is recorded in Donguibogam, 'Obiza looks at lungs and kidneys and heals tired, thirsty, The major pharmacological components of omija are lignin compounds such as iszanidine and gominin, which are effective for nourishing and tonic effects, and are useful for stimulating brain rotation, enhancing central nervous system function, improving blood circulation, treating chronic hepatitis, Diarrhea is effective. In addition, the extract of Omija has been shown to have antibacterial effect against various pathogenic microorganisms, and it has been proved that the intestinal bacterial flora is improved and the intestinal inflammation is suppressed.
그러나, 아직까지 오미자를 이용하여 안전성을 확보하면서, 체내 흡수율 및 그 효능을 최대화하고, 다양한 생리 작용의 상승 효과를 통하여 질병을 효율적으로 예방하고, 면역력 증진에 기여할 수 있는 생약 조성물에 대한 연구는 실질적으로 미미한 상태이다.
However, studies on herbal compositions which can effectively prevent diseases and enhance immunity by maximizing the absorption rate and efficacy of the body by using omiza and securing safety, synergistic effects of various physiological functions, .
본 발명은 유산균을 활용한 발효 기술을 통하여 안전성을 확보하면서 체내 흡수율 및 효능을 최대화하고, 다양한 생리 작용의 상승 효과를 통하여 질병을 효율적으로 예방하고, 우수한 항균 및 면역 증강 효과를 갖는 오미자 발효물 및 이를 포함하는 항균 및 면역 증강 조성물을 제공하는데 그 목적이 있다.
The present invention relates to a fermentation product of Omija fermented product having an excellent antibacterial and immune enhancing effect by effectively preventing diseases through maximizing the absorption rate and efficacy of the body while ensuring safety through fermentation technology utilizing lactic acid bacteria, And to provide an antibacterial and immunomodulating composition containing the same.
상기 과제를 해결하기 위한 본 발명의 일 측면은 오미자 추출물을 유산균으로 발효시킨 오미자 발효물을 제공한다.One aspect of the present invention to solve the above problems provides an omelet fermented product obtained by fermenting an extract of Omiza with lactic acid bacteria.
또한, 본 발명의 다른 일 측면은 오미자를 추출하여, 추출물을 형성하는 단계; 및 상기 오미자 추출물에 유산균을 접종하여 발효시키는 단계를 포함하는 오미자 발효물의 제조방법을 제공한다.According to another aspect of the present invention, there is provided a method for preparing an extract, comprising: extracting an omija to form an extract; And a step of inoculating the above-mentioned Omiza extract with lactic acid bacteria and fermenting the same.
본 발명의 일 측면에서, 상기 유산균은 L. plantarum VITA-L02(KCTC 12030BP)인 것을 특징으로 한다.In one aspect of the present invention, the lactic acid bacterium is L. plantarum VITA-L02 (KCTC 12030BP).
또한, 본 발명의 또 다른 일 측면은 본 발명의 오미자 발효물을 함유하는 항균 및 면역 증강용 사료 조성물을 제공한다.According to another aspect of the present invention, there is provided an antimicrobial and immunostimulating feed composition containing a fermented product of Omija of the present invention.
또한, 본 발명의 또 다른 일 측면은 본 발명의 오미자 발효물을 함유하는 항균 및 면역 증강용 약학 조성물을 제공한다.According to another aspect of the present invention, there is provided a pharmaceutical composition for antibacterial and immunological enhancement comprising the fermented product of Omija of the present invention.
또한, 본 발명의 또 다른 일 측면은 본 발명의 오미자 발효물을 함유하는 항균 및 면역 증강용 식품 조성물을 제공한다.
Still another aspect of the present invention provides an antimicrobial and immunostimulatory food composition containing the fermented product of Omija of the present invention.
본 발명에 따르면 항균 활성이 우수한 유산균주를 선정하고, 오미자의 최적 발효 조건을 설계함으로써 항균 및 면역 활성이 현저하게 향상되고, 체내 흡수율이 증가된 오미자 발효물을 얻을 수 있다.According to the present invention, by selecting lactic acid bacteria having excellent antimicrobial activity and designing optimum fermentation conditions of the omiza, it is possible to obtain an Omija fermented product in which the antibacterial and immune activity are remarkably improved and the absorption rate in the body is increased.
따라서, 이러한 오미자 발효물은 동물 사료 조성물뿐만 아니라, 식품 조성물이나 약학 조성물 등의 다양한 분야에 적용되어 체내 흡수율 및 다양한 생리 작용의 상승 효과를 통하여 우수한 면역 증강 효능 및 항균 효능을 발휘함으로써 질병을 효율적으로 예방하고, 면역력 증진에 기여할 수 있다.Therefore, such a fermented product of Omiza is applied not only to an animal feed composition but also to various fields such as a food composition and a pharmaceutical composition, and exhibits excellent immunity enhancing effect and antimicrobial effect through a synergistic effect of absorption rate and various physiological functions in the body, And can contribute to the promotion of immunity.
또한, 본 발명에 따른 오미자 발효물을 포함하는 항균 및 면역 증강 조성물은 독성이나 내성 문제를 일으키지 않는 생약 발효 조성물로 안전성이 확보되어 있으므로, 기존 항생제의 대체 물질로써 적용될 수 있다.In addition, the antimicrobial and immunomodulating composition containing the fermented product according to the present invention can be applied as a substitute for conventional antibiotics because it is a safe fermented herbal composition which does not cause toxicity or resistance problems.
도 1은 실시예 1에서 선정된 균주의 16S rDNA를 이용한 계통분석 결과를 나타내는 도이다.
도 2는 오미자 발효 전후의 면역 활성 시험 결과를 나타내는 그래프이다.
도 3은 본 발명에 이용된 균주인 L. plantarum VITA-L02(KCTC 12030BP)의 면역 활성 시험 결과를 나타내는 그래프이다.
도 4는 실시예 4에 따른 기간중 평균 증체량 측정결과를 나타내는 그래프이다.
도 5는 실시예 4에 따른 기간중 사료 요구율 측정결과를 나타내는 그래프이다.
도 6은 실시예 4에 따른 분변내 대장균군의 변화를 나타내는 그래프이다.
도 7은 실시예 4에 따른 분변내 유산균군의 변화를 나타내는 그래프이다.FIG. 1 is a diagram showing a systematic analysis result using 16S rDNA of the strain selected in Example 1. FIG.
2 is a graph showing the results of immunological activity test before and after Omija fermentation.
3 is a graph showing the results of immunological activity test of L. plantarum VITA-L02 (KCTC 12030BP) used in the present invention.
4 is a graph showing the results of average weight gain during the period according to the fourth embodiment.
5 is a graph showing the results of the feed demand ratio measurement in the period according to the fourth embodiment.
6 is a graph showing changes in the coliform bacteria in feces according to Example 4. Fig.
7 is a graph showing changes in the fecal lactic acid bacteria group according to Example 4. Fig.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 본 발명의 기술적 사상을 용이하게 실시할 수 있을 정도로 상세히 설명하기 위하여, 본 발명의 바람직한 실시예를 설명하기로 한다.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.
본 발명에 있어서는 유산균을 이용하여 오미자 추출물을 발효시킴으로써 항균 활성 및 면역 활성을 갖는 오미자 발효물을 얻을 수 있다.In the present invention, the Omija extract can be fermented using lactic acid bacteria to obtain an Omija fermented product having antimicrobial activity and immunological activity.
일 형태에서, 오미자 발효에 이용되는 유산균은 L. plantarum VITA-L02(KCTC 12030BP)이다.In one form, the lactic acid bacterium used for Omija fermentation is L. plantarum VITA-L02 (KCTC 12030BP).
본 발명자들은 전국 각지의 전통발효식품으로부터 항균 활성이 우수한 L. plantarum VITA-L02(KCTC 12030BP) 유산균주를 선별하여 오미자 발효에 이용하였다. 선별된 L. plantarum VITA-L02(KCTC 12030BP)는 병원균 9 종 (E. coli , S. typhimurium, S. aureus , S. enteritidis, S. epidermidis, C. freundii, E. cloacae, K. pneumoniae, S. flexneri)에 대한 항균 활성 시험결과 다른 균주에 비하여 우수한 항균 활성을 갖는 것으로 나타났다.The present inventors selected L. plantarum VITA-L02 (KCTC 12030BP) lactic acid bacteria having excellent antimicrobial activity from traditional fermented foods from all over the country and used them for Omija fermentation. L. plantarum VITA-L02 (KCTC 12030BP) was isolated from nine species of pathogens ( E. coli , S. typhimurium, S. aureus , S. Enteritidis , S. epidermidis , C. freundii , E. cloacae , K. pneumoniae , and S. flexneri ) showed excellent antimicrobial activity compared to other strains.
또한, L. plantarum VITA-L02(KCTC 12030BP) 유산균주는 그 자체로서는 면역 증강 효능을 나타내지 않지만, 이 유산균주를 이용한 오미자 발효물은 면역 활성의 지표인 TNF-α의 분비가 농도의존적으로 증가하여 면역 증강 효능을 나타낸다.In addition, the lactic acid bacteria of L. plantarum VITA-L02 (KCTC 12030BP) itself does not exhibit immunostimulating effect, but the secretion of TNF-α, which is an index of immune activity, Exhibit an enhancing effect.
본 발명에 있어서는 이와 같이 선정된 항균 활성이 우수한 유산균주를 이용하여 오미자 추출물을 발효시킴으로써, 발효의 일반적 이점, 예를 들어, 미생물의 분해작용에 의한 새로운 활성성분의 생성, 독성의 감소, 저장성 향상, 흡수가 용이한 저분자 물질로의 전환 효과와 함께 우수한 항균 및 면역 증강 효능을 동시에 발휘할 수 있다.In the present invention, by fermenting the Schizandra chinensis extract with the lactic acid bacteria having excellent antimicrobial activity, the general advantage of fermentation, for example, the generation of new active ingredients due to the degradation of microorganisms, the reduction of toxicity, , It is possible to exhibit excellent antimicrobial and immunostimulating effects as well as the effect of converting into a low molecular substance which is easily absorbed.
유산균은 오미자 추출물 중량에 대하여 0.001~15 중량%, 바람직하게는 0.01~10 중량%, 더욱 바람직하게는 약 1 중량%의 양으로 접종될 수 있다. 유산균의 접종량이 0.001 중량% 미만인 경우에는 발효 시간 내에 발효가 일어나지 않을 수 있으며, 15 중량%를 초과하는 경우에는 균의 생장이 저해되어 발효의 효과를 볼 수 없다.The lactic acid bacteria may be inoculated in an amount of 0.001 to 15% by weight, preferably 0.01 to 10% by weight, more preferably about 1% by weight, based on the weight of the Omija extract. When the inoculation amount of the lactic acid bacteria is less than 0.001% by weight, fermentation may not occur within the fermentation time, and when it exceeds 15% by weight, the growth of the bacteria is inhibited and the fermentation effect can not be observed.
일 실시예에서, 오미자 추출물은 일반적으로 천연물 추출에 사용되는 다양한 용매를 이용한 추출에 의하여 형성될 수 있으며, 예를 들어, 열수추출, 메탄올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성될 수 있다.In one embodiment, the Schizandra chinensis extract may be formed by extraction using various solvents generally used for natural product extraction, for example, by one or more methods selected from the group consisting of hot water extraction, methanol extraction and alcohol extraction .
오미자 추출물의 농도는 30~100 중량%, 바람직하게는 50~100 중량% 또는 50~99 중량%, 더욱 바람직하게는 약 100 중량% 또는 약 99 중량%일 수 있다. 오미자 추출물의 농도가 30 중량% 미만인 경우에는 면역 활성 및 항균 활성을 보장할 수 없다.The concentration of the Omiza extract may be 30 to 100% by weight, preferably 50 to 100% by weight or 50 to 99% by weight, more preferably about 100% by weight or about 99% by weight. When the concentration of Omiza extract is less than 30% by weight, immunity and antimicrobial activity can not be guaranteed.
일 실시예에서, 오미자 추출물은 일 이상의 탄소원 및 일 이상의 질소원을 더 포함할 수 있다.In one embodiment, the Schizandra chinensis extract may further comprise one or more carbon sources and one or more nitrogen sources.
탄소원 및 질소원은 각각 오미자 추출물 중량에 대하여 1~20 중량%, 바람직하게는 3~10 중량%의 양으로 포함될 수 있다. 탄소원 및 질소원의 첨가량이 각각 오미자 추출물 중량에 대하여 1 중량% 미만인 경우에는 유산균의 기본 생장이 저하되어 충분한 발효가 제한될 수 있으며, 20 중량%를 초과하는 경우에는 첨가된 탄소원 및 질소원이 주로 이용되어, 오미자 내에 함유된 유효성분을 이용한 발효의 효율이 저하될 수 있다.The carbon source and the nitrogen source may be contained in an amount of 1 to 20% by weight, preferably 3 to 10% by weight, based on the weight of the Omija extract, respectively. When the amount of the carbon source and the amount of the nitrogen source are less than 1% by weight based on the weight of the extract, respectively, the basic growth of the lactic acid bacterium is lowered and sufficient fermentation may be restricted. When the amount is more than 20% by weight, , The efficiency of fermentation using the active ingredient contained in the omisza may be lowered.
탄소원은 글루코오스, 말토오스, 수크로오스, 프럭토오스, 만노오스, 락토오스, 크실로스, 갈락토오스, 옥수수 전분 및 가용성 전분으로 이루어진 군으로부터 선택되는 일 이상일 수 있다.The carbon source may be one or more selected from the group consisting of glucose, maltose, sucrose, fructose, mannose, lactose, xylose, galactose, corn starch and soluble starch.
이 중, 유산균의 생장 효율 증가와 항균 활성 측면에서 글루코오스가 특히 바람직하다.Of these, glucose is particularly preferable in terms of increasing the growth efficiency of lactic acid bacteria and antimicrobial activity.
질소원은 트립톤, 맥아 추출물, 질산칼륨, 황산암모늄, 염화암모늄, 질산암모늄, 카제인, 콩 단백질 및 효모 추출물로 이루어진 군으로부터 선택되는 일 이상일 수 있다.The nitrogen source may be one or more selected from the group consisting of tryptone, malt extract, potassium nitrate, ammonium sulfate, ammonium chloride, ammonium nitrate, casein, soy protein and yeast extract.
이 중, 유산균의 생장 효율 증가와 항균 활성 측면에서 황산암모늄, 콩 단백질 및 효모 추출물로 이루어진 군으로부터 선택되는 일 이상이 특히 바람직하다.Of these, the one or more selected from the group consisting of ammonium sulfate, soybean protein and yeast extract is particularly preferable in view of the increase in the growth efficiency of lactic acid bacteria and the antibacterial activity.
본 발명의 다른 일 측면은 오미자를 추출하여, 추출물을 형성하는 단계; 및 상기 오미자 추출물에 유산균을 접종하여 발효시키는 단계를 포함하는 오미자 발효물의 제조방법에 관한 것이다.According to another aspect of the present invention, there is provided a method of extracting omiza, And a step of inoculating the Omiza extract with lactic acid bacteria and fermenting the same.
일 형태에서, 오미자 추출물의 발효에 이용되는 유산균은 L. plantarum VITA-L02(KCTC 12030BP)이다.In one form, the lactic acid bacterium used for the fermentation of Omiza extract is L. plantarum VITA-L02 (KCTC 12030BP).
오미자 추출물의 형성 단계는 일반적으로 천연물 추출에 사용되는 다양한 용매를 이용한 추출에 의하여 이루어질 수 있으며, 예를 들어, 열수추출, 메탄올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 이루어질 수 있다.The step of forming the extract of Omiza may generally be carried out by extraction using various solvents used for extracting natural products, for example, by one or more methods selected from the group consisting of hot water extraction, methanol extraction and alcohol extraction .
일 형태에서, 오미자 추출물의 형성 단계는 오미자에 증류수를 첨가하는 단계; 60~130℃의 온도에서 30~240분 동안 열수추출하는 단계; 및 여과하는 단계를 포함한다.In one form, the step of forming an Omija extract comprises the steps of adding distilled water to the Omija; Hydrothermal extraction at a temperature of 60 to 130 DEG C for 30 to 240 minutes; And filtering.
일 형태에서, 오미자 추출물 형성 후에, 오미자 추출물의 농도를 30~100 중량%, 바람직하게는 50~100 중량% 또는 50~99 중량%, 더욱 바람직하게는 약 100 중량% 또는 약 99 중량%로 조절하는 단계를 더 포함할 수 있다.In one form, after the formation of the Omija extract, the concentration of the Omija extract is adjusted to 30 to 100 wt%, preferably 50 to 100 wt% or 50 to 99 wt%, more preferably about 100 wt% or 99 wt% The method comprising the steps of:
또한, 전술한 바와 같이 오미자 추출물에 일 이상의 탄소원 및 일 이상의 질소원을 첨가함으로써, 발효 조건을 더욱 최적화할 수 있다.Further, by adding one or more carbon sources and one or more nitrogen sources to the Omiza extract as described above, the fermentation conditions can be further optimized.
발효 단계는 25~37℃의 온도에서 6~60시간 동안 이루어지는 것이 바람직하다.The fermentation step is preferably carried out at a temperature of 25 to 37 DEG C for 6 to 60 hours.
발효 단계에 있어서, 유산균은 오미자 추출물 중량에 대하여 0.001~15 중량%, 바람직하게는 0.01~10 중량%, 더욱 바람직하게는 약 1 중량%의 양으로 접종될 수 있다.In the fermentation step, the lactic acid bacteria may be inoculated in an amount of 0.001 to 15% by weight, preferably 0.01 to 10% by weight, more preferably about 1% by weight, based on the weight of the Omija extract.
본 발명의 또 다른 일 실시예는 본 발명에 따른 유산균으로 발효시킨 오미자 발효물을 함유하는 항균 및 면역 증강용 사료 조성물에 관한 것이다.Another embodiment of the present invention relates to an antimicrobial and immunostimulating feed composition containing a fermented Omija fermented by a lactic acid bacterium according to the present invention.
사료 조성물 중의 오미자 발효물의 함량은 급여 가축의 종, 주령, 체중, 및 사육 조건 등에 따라 적절히 선택될 수 있으며, 사료 전체 중량에 대하여 0.01~10 중량%의 비율일 수 있다.The content of the fermented product of Omija in the feed composition can be appropriately selected according to species, age, body weight, feeding conditions and the like of the feed livestock, and may be a ratio of 0.01 to 10% by weight based on the total weight of the feed.
본 발명의 항균 및 면역 증강용 사료 조성물은 기술분야에 공지된 사료 제조방법에 따라 제조될 수 있으며, 예를 들어, 각종 사료 원료 또는 배합사료와 본 발명의 오미자 발효물을 혼합한 후, 추가적인 가공 공정, 예를 들어 펠렛 형태로의 성형 또는 과립 등의 형태로의 절단 단계 등을 더 수행함으로써 제조될 수 있다.The antimicrobial and immunostimulating feed composition of the present invention can be prepared according to a method of manufacturing feeds known in the art. For example, after mixing various feedstuffs or compounded feeds with the fermented product of the present invention, For example, a step in the form of pellets or a step in the form of granules or the like.
본 발명의 항균 및 면역 증강용 사료 조성물의 구성성분, 조성, 제조방법, 급여방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.It is apparent to those skilled in the art that the composition, composition, manufacturing method, feeding method and the like of the antimicrobial and immunostimulating feed composition of the present invention can be suitably selected from conventional techniques known in the art.
본 발명의 또 다른 일 실시예는 본 발명에 따른 유산균으로 발효시킨 오미자 발효물을 함유하는 항균 및 면역 증강용 약학 조성물에 관한 것이다.Another embodiment of the present invention relates to a pharmaceutical composition for antibacterial and immunological enhancement containing a fermented product of Omija fermented with lactic acid bacteria according to the present invention.
본 발명의 항균 및 면역 증강용 약학 조성물은 기술분야에 공지된 통상의 방법에 따라, 산제, 과립제, 정제, 캡슐제와 같은 고형 제제, 및 현탁제, 유제, 시럽제와 같은 액상 제제, 주사제, 외용제, 좌제 등의 형태로 제제화되어 경구 또는 비경구 투여될 수 있다.The pharmaceutical composition for antibacterial and immunological enhancement of the present invention may be formulated into solid preparations such as powders, granules, tablets, capsules, and liquid preparations such as suspensions, emulsions and syrups, injections, , Suppositories, etc., and may be administered orally or parenterally.
제제화 방법은 기술분야에 공지된 통상의 방법에 따라 수행될 수 있으며, 예를 들어, 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 부형제, 희석제 등을 사용하여 적절하게 이루어질 수 있다.The formulation method can be carried out according to a conventional method known in the art and can be suitably carried out using, for example, a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, a lubricant, an excipient, .
본 발명의 오미자 발효물의 투여량은 투여 대상의 연령, 성별, 체중, 상태, 질병의 정도, 약물의 형태, 투여 경로 및 기간에 따라 적절히 선택될 수 있으며, 예를 들어 0.1~2000 ㎎, 바람직하게는 1~500 ㎎이다.The dosage of the fermented product of the present invention can be appropriately selected depending on the age, sex, weight, condition, degree of disease, form of the drug, route of administration and period of administration and is, for example, 0.1 to 2000 mg, Is 1 to 500 mg.
본 발명의 항균 및 면역 증강용 약학 조성물의 제제화 방법, 투여량, 투여 경로, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다.It will be apparent to those skilled in the art that the method of formulation, dose, route of administration, components and the like of the pharmaceutical composition for antibacterial and immunological enhancement of the present invention can be suitably selected from conventional techniques known in the art.
또한, 본 발명의 또 다른 일 측면은 본 발명에 따른 유산균으로 발효시킨 오미자 발효물을 함유하는 항균 및 면역 증강용 식품 조성물에 관한 것이다.According to another aspect of the present invention, there is provided an antibacterial and immunological enhancing food composition containing a fermented product of Omija fermented with lactic acid bacteria according to the present invention.
유산균, 특히 L. plantarum VITA-L02(KCTC 12030BP)을 이용하여 발효시킨 오미자 발효물은 인체 및 동물에 안전한 유산균을 이용하여 독성이나 부작용이 없고 안전성이 확보될 수 있으므로, 다양한 형태의 식품 조성물에 첨가될 수 있다.The fermented Omija fermented by using lactic acid bacteria, especially L. plantarum VITA-L02 (KCTC 12030BP), is safe and safe from toxicity or side effects by using lactic acid bacteria which are safe for human and animal, .
본 발명에 따른 항균 및 면역 증강용 식품 조성물은 기술분야에 공지된 통상의 방법에 따라 각종 소스나 양념류, 우유, 버터, 요구르트 등의 유제품, 빵, 케이크, 쿠키, 면류 등의 밀가루 제품, 음료 등의 다양한 형태로 제조될 수 있다.The antimicrobial and immunoconjugate food composition according to the present invention can be applied to various types of sauces, condiments, dairy products such as milk, butter, yogurt, flour products such as bread, cakes, cookies, Can be manufactured in various forms.
식품 조성물 중의 오미자 발효물의 함량은 식품의 형태, 풍미, 맛 등을 고려하여 적절하게 선택될 수 있으며, 예를 들어 식품 조성물 전체 중량에 대하여 0.01~10 중량%의 범위일 수 있다.The content of the fermented Omija in the food composition may be appropriately selected in consideration of the shape, flavor, taste, etc. of the food, and may be, for example, in the range of 0.01 to 10% by weight based on the total weight of the food composition.
본 발명의 항균 및 면역 증강용 식품 조성물의 형태, 조성 및 제조방법 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있음이 통상의 기술자에게 명백하다. It will be apparent to those skilled in the art that the form, composition and manufacturing method of the antimicrobial and immunostimulating food composition of the present invention can be appropriately selected from conventional techniques known in the art.
이와 같이, 본 발명에 따른 유산균을 이용하여 발효시킨 오미자 발효물은 사료 조성물뿐만 아니라, 식품 조성물이나 약학 조성물 등의 다양한 분야에 적용되어 체내 흡수율 및 다양한 생리 작용의 상승 효과를 통하여 우수한 면역 증강 효능 및 항균 효능을 발휘함으로써 질병을 효율적으로 예방하고, 면역력 증진에 기여할 수 있다.
As described above, the fermented Omija fermented by the lactic acid bacteria according to the present invention is applied not only to the feed composition but also to various fields such as food composition and pharmaceutical composition, and has a superior absorption enhancing effect By exhibiting antibacterial efficacy, disease can be efficiently prevented and it can contribute to the improvement of immunity.
이하, 본 발명을 실시예에 의하여 더욱 상세하게 설명한다. 그러나 하기 실시예는 본 발명을 예시하는 것일 뿐이며, 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in more detail by way of examples. However, the following examples are illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
[[ 실시예Example ]]
1. 유산균의 분리 및 선발1. Isolation and selection of lactic acid bacteria
(1) 실험 방법(1) Experimental method
1) 시료의 수집1) Collection of sample
전국 각지에서 제조된 전통발효식품으로부터 시료를 수집하였다. 확보된 전통발효식품 시료는 호모게나이저(homogenizer)를 이용하여 파쇄하고, 균질하게 혼합한 후 -20℃에서 냉동 보관하며 사용하였다.Samples were collected from traditional fermented foods manufactured in various parts of Japan. The obtained traditional fermented food samples were crushed using a homogenizer, mixed homogeneously and stored frozen at -20 ° C.
2) 식물유래 유산균의 분리2) Isolation of plant-derived lactic acid bacteria
① 인공 위산 및 인공 담즙액으로부터 내성을 갖는 균주의 분리① Isolation of strains resistant to artificial gastric acid and artificial bile
사용하고자 하는 시료를 호모게나이저를 이용하여 파쇄하고 균질하게 혼합하였다. 이를 멸균된 PBS 완충액과 혼합한 후, 원심분리를 통해 펠렛을 회수하였다. 회수된 펠렛에 10 ㎖의 인공 위산(0.3% 펩신을 함유하는 MRS 브로스 용액(broth solution), pH 2.5)을 첨가한 후, 37℃에서 1시간 동안 방치하였다. 원심분리를 통하여 펠렛을 최수하고, 1 ㎖의 인공 담즙액(0.3% 돼지 담즙을 함유하는 MRS 브로스 용액)을 첨가하여, 37℃에서 1시간 동안 방치하였다. 원심분리를 통하여 펠렛을 회수하고, 1 ㎖의 PBS 완충액으로 현탁한 후, 10진 희석하여 MRS 한천 배지에 도말하였다. 도말된 배지를 37℃에서 36~48시간 동안 배양한 후, 형성된 콜로니를 인공 위산 및 인공 담즙액에 내성을 갖는 균주로 판단하여 선별하였다.The samples to be used were disrupted using a homogenizer and mixed homogeneously. After mixing with sterile PBS buffer, the pellet was recovered by centrifugation. To the recovered pellet, 10 ml of artificial gastric acid (MRS broth solution containing 0.3% pepsin, pH 2.5) was added and left at 37 占 폚 for 1 hour. The pellet was suspended by centrifugation, and 1 ml of artificial bile solution (MRS broth solution containing 0.3% porcine bile) was added and left at 37 캜 for 1 hour. The pellet was recovered by centrifugation, suspended in 1 ml of PBS buffer, decanted, and plated on MRS agar medium. The cultured medium was incubated at 37 ° C for 36-48 hours, and the colonies formed were judged to be strains resistant to artificial gastric acid and artificial bile juice.
② 유산균 유사 균주의 선별② Selection of lactobacillus-like strains
인공 위산 및 인공 담즙액 내성 균주를 BCP 한천 배지에 피킹한 후, 37℃에서 하룻밤 동안 배양하였다. 콜로니 주위의 색 변화로 산생성의 유무를 판단하여 콜로니 주변이 노란색으로 변한 것을 유산균으로 선별하였다.Artificial gastric acid and artificial bile acid resistant strains were picked in BCP agar medium and cultured overnight at 37 ° C. The presence of acid production was judged by the color change around the colonies, and the change of the colony surroundings into yellow was selected by lactic acid bacteria.
3) 항균 활성 실험: 3) Antibacterial activity test: 프로바이오틱Probiotic (( probioticprobiotic ) 유산균의 배양 ) Culture of lactic acid bacteria 대사산물(균체가 제거된 배양상징액)에Metabolism (culture supernatant from which cells are removed) 대한 항균 활성 측정 Antimicrobial activity measurement
밀러-힌톤 한천(Muller-Hinton Agar(MHA)) 스퀘어 디쉬 (12×12 ㎝)에 1×109 cfu/㎖로 배양된 다양한 병원성 세균 (E. coli, Salmonella typhimurium, Staphylococcus aureus, Salmonella enteritidis , Staphylococcus epidermidis, Citrobacter freundii, Enterobacter cloacae, Klebsiella pneumoniae, Shigella flexneri) 배양액을 접종한 후, 멸균된 면봉을 이용해 고르게 도말하였다.Various pathogenic bacteria ( E. coli) cultivated in Muller-Hinton Agar (MHA) square dish (12 × 12 cm) at 1 × 10 9 cfu / ml. coli , Salmonella typhimurium , Staphylococcus aureus , Salmonella enteritidis , Staphylococcus epidermidis , Citrobacter freundii , Enterobacter cloacae , Klebsiella pneumoniae , Shigella flexneri ), and then smoothed evenly using a sterile cotton swab.
병원성 세균이 도말된 스퀘어 디쉬 위에 페이퍼 디스크 (직경 8 ㎜, 두께 1.5 ㎜)를 올린 후, 선별된 프로바이오틱 유산균의 배양상징액 (MRS 브로스에서 배양된 프로바이오틱 유산균 배양액을 4℃에서, 7,000 rpm으로, 10분 동안 원심분리 하여 상등액을 회수한 후 0.2 ㎛ 실린지 필터를 이용하여 제균)을 페이퍼 디스크 위에 적하하였다. 37℃에서 투명환이 관찰될 때까지 적정 시간 배양한 후, 생성된 투명환의 크기로 항균 활성을 비교하였다.After a paper disk (diameter: 8 mm, thickness: 1.5 mm) was placed on a square dish on which pathogenic bacteria had been streaked, the culture broth of the probiotic lactic acid bacteria cultured in MRS broth was incubated at 7,000 rpm , The supernatant was recovered by centrifugation for 10 minutes, and sterilized using a 0.2 mu m syringe filter) was dropped onto a paper disk. After incubation for an appropriate period of time until a transparent ring was observed at 37 캜, the antimicrobial activity was compared with the size of the produced transparent ring.
4) 4) 계통학적Systematic 분석 - 16S Analysis - 16S rDNArDNA 염기서열을 이용한 계통분석 Systematic analysis using nucleotide sequence
균체를 회수하고 100 ㎕ STES 완충액 (0.4 M NaCl, 0.2 M Tris-HCl (pH 7.6), 0.01 M EDTA, 1% SDS)에 현탁하였다. 현탁액에 글래스 비드를 첨가하고 세포를 파쇄하기 위하여 마이크로 튜브 믹서(Micro tube mixer) MT-360 (TOMY) 를 이용하여 5분간 강하게 교반하였다. 세포 파쇄 후, 페놀 추출(Phenol extraction)을 실시하고, 상등액에 RNase A 5 ㎕를 첨가한 다음, 37℃에서 1시간 반응시켰다. 반응 후, 페놀 추출을 다시 실시하고, 에탄올 침전을 실시하여 DNA를 회수하였다.The cells were recovered and suspended in 100 μl of STES buffer (0.4 M NaCl, 0.2 M Tris-HCl (pH 7.6), 0.01 M EDTA, 1% SDS). Glass beads were added to the suspension and the cells were vigorously agitated for 5 minutes using a micro-tube mixer MT-360 (TOMY) to disrupt the cells. After cell disruption, phenol extraction was performed, and 5 쨉 L of RNase A was added to the supernatant, followed by reaction at 37 째 C for 1 hour. After the reaction, phenol extraction was carried out again, and ethanol precipitation was carried out to recover the DNA.
16S rDNA는 PCR 방법을 통하여 증폭하였으며 사용된 프라이머는 아래와 같다:16S rDNA was amplified by PCR method and the primers used were as follows:
포워드 프라이머; 5'-GA GTT TGA TCC TGG CTC AG-3' (E. coli numbering system, positions 9 - 27)Forward primer; 5'-GA GTT TGA TCC TGG CTC AG-3 '( E. coli numbering system, positions 9-27)
리버스 프라이머: 5'-GGT TAC CTT GTT ACG ACT T-3' (E. coli numbering system, positions 1,492 - 1,510)Reverse primer: 5'-GGT TAC CTT GTT ACG ACT T-3 '( E. coli numbering system, positions 1,492-1,510)
PCR 반응의 조건은 아래와 같이 실시하였다:The conditions of the PCR reaction were as follows:
총 30 사이클로, 각 사이클은 변성(Denaturation)을 위하여 94℃에서 60초, 어닐링(Annealing)을 위하여 50℃에서 60초, 확장(Extension)을 위하여 72℃에서 90초로 실시하였다.Each cycle was carried out for 60 seconds at 94 DEG C for denaturation, 60 seconds at 50 DEG C for annealing, and 90 seconds at 72 DEG C for extension.
분리균주의 16S rDNA 염기서열은 관련된 Genus를 대표하는 비교균주의 염기서열과 함께 CLUSTAL W Software Program을 이용하여 정렬하였다.The 16S rDNA sequences of the isolates were sorted using the CLUSTAL W Software Program with the nucleotide sequences of the comparative strains representing the relevant Genus.
Evolutionary Distance Materices는 Kimura Two Parameter 방법에 근거하여 작성하였고, PHYLIP Package version 3.572가 제공하는 Neighbour - Joining Method Tool을 이용하여 계통수를 작성하였다.
The Evolutionary Distance Materices were constructed based on the Kimura Two Parameter method and the Neighbor - Joining Method Tool provided by PHYLIP Package version 3.572.
(2) 실험결과(2) Experimental results
1) 우수 항균 활성 보유 유산균의 선별1) Selection of lactic acid bacteria having excellent antimicrobial activity
유산균주 페이퍼 디스크 항균 활성 실험 결과를 하기 표 1에 나타낸다. 표 1에 나타낸 바와 같이, 병원균 9 종 (E. coli , S. typhimurium , S. aureus , S. enteritidis, S. epidermidis, C. freundii, E. cloacae, K. pneumoniae, S. flexneri)을 대상으로 디스크 확산법(Disc Diffusion Method) (8 ㎜ 페이퍼 디스크 사용)를 이용하여 우수 항균 활성을 보유한 1 균주(VITA-L02)를 선별하였다. Table 1 shows the results of the antimicrobial activity of the paper disks of the lactic acid bacteria. As shown in Table 1, the nine kinds of target pathogens (E. coli, S. typhimurium, S. aureus, S. Enteritidis, S. epidermidis, C. freundii, E. cloacae, K. pneumoniae, S. flexneri) One strain (VITA-L02) with excellent antimicrobial activity was selected using the Disc Diffusion Method (using 8 mm paper disk).
2) 선발된 유산균의 계통분석2) Systematic analysis of selected lactic acid bacteria
16S rDNA를 이용한 계통분석 결과를 도 1에 나타낸다. 도 1에 도시된 바와 같이, 16S rDNA를 이용한 계통분석 결과 최종선정된 균주(VITA-L02)는 Lactobacillus plantarum과 근연관계를 형성하고 있음을 알 수 있었다.
The results of systematic analysis using 16S rDNA are shown in Fig. As shown in FIG. 1, the systematic analysis using 16S rDNA revealed that the final selected strain (VITA-L02) was closely related to Lactobacillus plantarum .
2. 오미자 2. Omiza 발효물의Fermented 제조 Produce
(1) 실험방법(1) Experimental method
1) 오미자 1) Omiza 열수추출물의Of hot-water extract 제조 Produce
오미자 100 g에 10배의 증류수를 첨가하여 105℃에서 150분간 열수추출한 후, 0.25 ㎛ 필터를 이용하여 여과하여 제조하였다.10 g of distilled water was added to 100 g of Omija, and the mixture was subjected to hot water extraction at 105 ° C for 150 minutes, followed by filtration using a 0.25 μm filter.
2) 발효조건 설계2) Design of fermentation condition
① 유산균 발효를 위한 오미자 열수추출물 적정 농도 설정① Proper concentration of Omija hot water extract for fermentation of lactic acid bacteria
오미자 열수추출물을 멸균 증류수와 희석하여 각각 100%, 75%, 50%의 희석액을 제조하였다. 항균 활성 시험결과 활성이 가장 뛰어난 것으로 나타난 L. plantarum VITA-L02 균주를 MRS 브로스에 2% 접종하고 37℃ 배양기에서 12시간 동안 정치배양하여 접종액을 제조하였다.100%, 75%, and 50% diluted solutions were prepared by diluting Omija hot - water extract with sterilized distilled water. The inoculum was prepared by inoculating L. plantarum VITA-
준비된 농도별 열수추출물에 VITA-L02 배양액을 1% 접종하여 37℃ 배양기에서 24시간까지 발효를 실시하였다. 0h, 12h, 24h 각 단계별로 pH 미터를 이용하여 pH를 측정하고 10진 희석법을 이용하여 생균수를 측정하였다. The prepared hot-water extracts were inoculated with 1% of VITA-L02 culture medium and fermented in a 37 ° C incubator for 24 hours. PH was measured using a pH meter at 0 h, 12 h and 24 h, and the number of viable cells was measured using a decimal dilution method.
② 최적 발효조건 탐색② Search for optimal fermentation conditions
다양한 탄소원 및 질소원이 발효에 미치는 영향을 조사하여 최적의 발효조건을 탐색하였다.The effects of various carbon sources and nitrogen sources on the fermentation were investigated and the optimal fermentation conditions were investigated.
오미자 열수추출물에 글루코오스, 말토오스, 수크로오스, 프럭토오스, 만노오스, 락토오스, 크실로스, 갈락토오스, 옥수수 전분, 가용성 전분 등을 탄소원으로 하여 각각의 탄소원을 농도별로 첨가하였다.Each carbon source was added to the extract of Omija hot water with glucose, maltose, sucrose, fructose, mannose, lactose, xylose, galactose, corn starch and soluble starch as carbon sources.
오미자 열수추출물에 트립톤, 맥아 추출물, 질산칼륨, 황산암모늄, 염화암모늄, 질산암모늄, 카제인, 콩 단백질(Hydrolyzed Soy Peptone 304, Hydrolyzed Soy Peptone 309), 효모 추출물(Yeast Extract Springer 0202, Yeast Extract Springer 0250, Yeast Extract Pronal 5001) 등을 질소원으로 하여 각각의 질소원을 농도별로 첨가하였다.Yeast Extract Springer 0202, Yeast Extract Springer 0250, Yeast Extract Springer 0202, Yeast Extract Springer 0202, Yeast Extract Springer 0202, Yeast Extract Springer 0202, Yeast Extract Springer 0202, , Yeast Extract Pronal 5001) were used as the nitrogen sources, and the respective nitrogen sources were added by concentration.
각각의 질소원 및 탄소원이 첨가된 오미자 열수추출물에 VITA-L02 배양액을 1% 접종하여 37℃ 배양기에서 24시간까지 발효를 실시하였다.VITA-L02 culture medium was inoculated 1% in the hot water extract of Omija to which each nitrogen source and carbon source had been added, and fermentation was carried out in a 37 ° C incubator for 24 hours.
생균수 측정: 0h, 12h, 24h 각 단계별로 pH 미터를 이용하여 pH를 측정하고, 10진 희석법을 이용하여 생균수를 측정하였다.Measurement of viable cell count: The pH was measured using a pH meter at each of 0 h, 12 h and 24 h, and the number of viable cells was measured using a decimal dilution method.
발효 중 항균 활성 패턴분석 : 밀러 힌톤 한천 (MHA) 스퀘어 디쉬 (12×12 ㎝)에 1×109 cfu/㎖로 배양된 다양한 병원성 세균 (E. coli, Salmonella typhimurium, Staphylococcus aureus, Klebsiella pneumoniae) 배양액을 접종한 후, 멸균된 면봉을 이용해 고르게 도말하였다. 병원성 세균이 도말된 MHA 스퀘어 디쉬 위에 페이퍼 디스크 (직경 8 ㎜, 두께 1.5 ㎜)를 올린 후, 발효경과 중 각 조건별로 2시간 단위로 샘플을 취하여 페이퍼 디스크 위에 적하하였다. 37℃에서 투명환이 관찰될 때까지 적정 시간 배양한 후, 생성된 투명환의 크기로 항균 활성을 비교하였다.Analysis of antimicrobial activity patterns during fermentation: Various pathogenic bacteria ( E. coli) cultured at 1 × 10 9 cfu / ml in Miller Hinton agar (MHA) square dish (12 × 12 cm) coli , Salmonella typhimurium , Staphylococcus aureus , Klebsiella pneumoniae ) was inoculated and smoothed evenly using sterile cotton swabs. A paper disk (diameter: 8 mm, thickness: 1.5 mm) was placed on the MHA square dish on which pathogenic bacteria had been stained, and samples were taken every 2 hours for each condition during fermentation and dropped onto a paper disk. After incubation for an appropriate period of time until a transparent ring was observed at 37 캜, the antimicrobial activity was compared with the size of the produced transparent ring.
(2) 실험결과(2) Experimental results
가장 뛰어난 생장 효율 증가와 항균 활성을 나타낸 100% 열수추출물에 글루코오스 2%, 아세트산나트륨 0.5%, 황산암모늄 0.2%, 콩 단백질 1%, 효모 추출물 1% 첨가 조건으로 발효조건을 설계하였다.
Fermentation conditions were designed by adding 2% glucose, 0.5% sodium acetate, 0.2% ammonium sulfate, 1% soybean protein and 1% yeast extract to 100% hot water extract which showed the best growth efficiency and antibacterial activity.
3. 발효 전, 후의 항균 활성 및 면역증강효능 (3. Antimicrobial activity and immune enhancement before and after fermentation inin -- vitrovitro ))
(1) 실험방법(1) Experimental method
1) 항균 활성 실험1) Antimicrobial activity experiment
밀러 힌톤 한천 (MHA) 스퀘어 디쉬 (12×12 ㎝)에 1×109 cfu/㎖로 배양된 다양한 병원성 세균 (E. coli, Salmonella typhimurium, Staphylococcus aureus, Klebsiella pneumoniae , Salmonella enteritidis) 배양액을 접종한 후, 멸균된 면봉을 이용해 고르게 도말하였다. 병원성 세균이 도말된 MHA 스퀘어 디쉬 위에 페이퍼 디스크 (직경 8 ㎜, 두께 1.5 ㎜)를 올린 후, 발효 전, 후 샘플을 취하여 페이퍼 디스크 위에 적하하였다. 37℃에서 투명환이 관찰될 때까지 적정 시간 배양한 후, 생성된 투명환의 크기로 항균 활성을 비교하였다.Various pathogenic bacteria ( E. coli) cultured at 1 × 10 9 cfu / ml in Miller Hinton agar (MHA) square dish (12 × 12 cm). coli , Salmonella typhimurium , Staphylococcus aureus , Klebsiella pneumoniae , Salmonella enteritidis ), and then smoothed evenly using sterile cotton swabs. A paper disk (diameter: 8 mm, thickness: 1.5 mm) was placed on the MHA square dish on which pathogenic bacteria had been stained, and samples were taken before and after fermentation and dropped onto a paper disk. After incubation for an appropriate period of time until a transparent ring was observed at 37 캜, the antimicrobial activity was compared with the size of the produced transparent ring.
2) 면역 활성 실험(2) Immunization activity test ( TNFTNF -α 측정)-α measurement)
TNF-α는 주로 활성화된 대식세포(macrophage)에 의하여 생성되는 염증성 사이토카인으로서 세포성 면역반응에 중요한 역할을 하고, 숙주의 다른 사이토카인의 생성을 증가시킨다.TNF-α is an inflammatory cytokine produced mainly by activated macrophages and plays an important role in cellular immune responses and increases the production of other cytokines in the host.
면역 활성 실험에서 마우스 대식세포주인 RAW 264.7를 이용하였으며, 세포주는 10% FBS와 100 unit의 페니실린과 스트렙토마이신이 함유된 RPMI 1640 배지를 사용하여 5%의 CO2를 포함한 37℃의 포화 습도 공기 조건 하에서 배양하였다.The mouse macrophage cell line RAW 264.7 was used in the immunoactivity experiment. The cell line was cultured in RPMI 1640 medium containing 10% FBS and 100 units of penicillin and streptomycin at 37 ° C in a humidified air atmosphere of 5% CO 2 Lt; / RTI >
96웰 플레이트의 각각의 웰에 RAW 264.7 세포를 1×105 cells/㎖를 분주하고 RAW264.7 배양세포에 발효전 오미자 샘플 및 발효 샘플(오미자+VITA-L02)을 0.1%, 0.5%, 1%, 2%로 각각 희석하여 처리하였다. 유산균 샘플(VITA-L02)은 0.1%, 0.5%, 1%로 처리하였다(Control-normal media, LPS-E.coli Lipopolysaccaride).RAW 264.7 cells were added to each well of a 96-well plate at a rate of 1 × 10 5 cells / ml. RAW 264.7 cells were seeded with 0.1%, 0.5%, and 1% pre-fermented Omija and fermentation samples (Omiza + VITA-L02) %, And 2%, respectively. Lactobacillus samples (VITA-L02) were treated with 0.1%, 0.5%, and 1% (Control-normal media, LPS-E. coli Lipopolysaccaride).
18시간 후에(유산균 처리의 경우 12시간 및 24시간 후) 세포의 상층액을 얻고, TNF-α ELISA 키트로 분비된 TNF-α를 측정하였다. After 18 hours (12 hours and 24 hours in the case of lactobacillus treatment), the supernatant of the cells was obtained and the TNF-alpha secreted by the TNF-alpha ELISA kit was measured.
(2) 실험결과(2) Experimental results
1) 항균 활성 실험결과1) Results of antibacterial activity
오미자 발효 전후 페이퍼 디스크 항균 활성 실험 결과를 하기 표 2에 나타낸다. 표 2에 나타낸 바와 같이, 발효 전 오미자의 항균 활성은 오미자 발효물에서도 동등한 수준으로 유지되었으며, 특히 L. plantarum VITA-L02를 이용하여 발효된 오미자 발효물에서 더 높은 항균 활성을 나타내었다. The results of paper disk antimicrobial activity before and after the fermentation of Omiza are shown in Table 2 below. As shown in Table 2, the antimicrobial activity of Omija before fermentation was maintained at the same level in the fermented Omija fermented product. Especially, the fermented Omija fermented product using L. plantarum VITA-L02 showed higher antimicrobial activity.
2) 면역 활성 실험 결과2) Results of immunological activity test
각 샘플에 대한 TNF-α 측정결과를 도 2 및 3에 도시한다. 도 2 및 3에 도시된 바와 같이, 유산균(L. plantarum VITA-L02) 및 발효 전 오미자에서는 염증성 사이토카인인 TNF-α의 분비가 유도되지 않았으나 L. plantarum VITA-L02을 이용하여 발효된 오미자 발효물에서는 농도의존적으로 TNF-α의 분비가 유도되어 면역 증진 효능이 강화된 것을 알 수 있었다.
The results of TNF-a measurement for each sample are shown in Figures 2 and 3. As illustrated in Figures 2 and 3, the lactic acid bacteria (L. plantarum VITA-L02), and pre-fermentation Omija the inflammatory cytokine of the TNF-α did not induce the secretion L. plantarum VITA-L02 using a fermented fermentation Omija In water, the secretion of TNF-α was induced in a concentration-dependent manner, and the immunity enhancing effect was enhanced.
4. 사양시험(4. Specification test ( iviv -- vivovivo ))
(1) 실험방법(1) Experimental method
1) 사양시험설계1) Specifications Test design
① 시험군은 비처리군(대조군), 오미자 열수 추출물 급여군(오미자), 본 발명에 따른 오미자 발효물 급여군(오미자 발효물) 3개의 군으로 실험을 실시하였다.(1) Experimental groups were divided into three groups: untreated group (control group), Omiza hot water extract group (Omiza), and Omiza fermented food group (Omiza fermented product) according to the present invention.
② 실험은 이유자돈(약 28일령)으로 각 돈방당 10두씩 3반복하여 실험하였다.② The experiment was conducted by repeating the experiment three times with ten pens per each pound of weaning pig (about 28 days old).
③ 제형은 액상으로, 급여는 음수 투약기를 이용하여 음수의 1% 혼합급여방법을 사용하였다.③ The formulation was a liquid phase, and the feed was a 1% mixed feed method using a negative solution.
④ 처리기간은 총 5주간 실험하였다.④ The treatment period was 5 weeks.
⑤ 측정항목은 증체율, 사료섭취량, 사료요구율, 분변미생물총의 변화 등을 측정하였다. ⑤ The measurement items were the rate of growth, feed intake, feed conversion rate, and changes in fecal microbial count.
⑥ 통계처리는 SPSS ver.18을 이용하여 분석하였다. 평균값의 유의적인 차이는 던칸 다중 검정(Duncan's multiple test)에 의하여 검증하였고, p<0.05 수준에서의 유의차를 확인하였다.
⑥ Statistical analysis was performed using SPSS ver.18. Significant differences in means were verified by Duncan's multiple test and significant differences were found at p <0.05 level.
(2) 실험결과(2) Experimental results
1) One) 기간중During the period 평균 Average 증체량Weight gain
각 시험군에 대하여 측정된 평균 증체량 결과를 도 4에 도시한다. 도 4에 도시된 바와 같이, 평균 증체량은 오미자 발효물 급여군의 경우 14.08(㎏/d), 오미자 급여군의 경우 13.33(㎏/d), 대조군의 경우 12.08(㎏/d) 로 나타났다. 던칸 다중 검정 통계 검정 결과 3가지 처리군 모두 95% 신뢰수준에서 유의차(p<0.05)가 인정되었으며, 특히 본 발명에 따른 오미자 발효물 급여군에서 대조군에 비해 약 14.2%정도 평균 증체량이 증가함을 알 수 있었다.The measured average weight gain results for each test group are shown in FIG. As shown in FIG. 4, the average weight gain was 14.08 (kg / d) in the case of the Omija fermented product group, 13.33 (kg / d) in the case of Omiza and 12.08 (kg / d) in the control. The Duncan multiple test statistic showed that the difference of 95% confidence level (p <0.05) was recognized among the three treatment groups, and the average weight gain was increased by about 14.2% compared with the control group And it was found.
2) 사료 요구율2) Feeding rate
각 시험군에 대하여 측정된 사료 요구율 결과를 도 5에 도시한다. 도 5에 도시된 바와 같이, 사료 요구율은 본 발명에 따른 오미자 발효물 급여군의 경우 1.38로 가장 낮게 나타났으며, 오미자 급여군의 경우 1.39로 나타났다. 대조군은 1.42로 사료요구율이 가장 높게 나타났으나, 통계적인 유의성은 인정되지 않았다.The results of the measured feed rate for each test group are shown in FIG. As shown in FIG. 5, the feed conversion ratio was the lowest in the group of the Schizosaccharomyces pombe according to the present invention of 1.38, and it was 1.39 in the Schizophrenia group. The control group had the highest feed conversion ratio of 1.42, but no statistical significance was observed.
3) 3) 분변내In the feces 미생물 총의 변화 Changes in microbial counts
각 시험군에 대하여 측정된 분변내 미생물 총의 변화 결과를 도 6 및 7에 도시한다. 도 6에 도시된 바와 같이, 본 발명에 따른 오미자 발효물 급여군에 있어서, 대장균총의 경우 급여 전 약 1.45x108 cfu/g에서 약 3.3x104 cfu/g까지 점차 감소하는 경향을 보였다. 또한 도 7에 도시된 바와 같이, 유산균군의 경우 급여 전 약 8.25x105 cfu/g에서 3.75x107 cfu/g 수준으로 점차 증가하는 경향을 보였다. The results of the changes in microbial counts in the feces measured for each test group are shown in FIGS. 6 and 7. FIG. As shown in FIG. 6, in the group fed with the fermented Omija fermented product according to the present invention, the total amount of E. coli showed a tendency to decrease gradually from about 1.45x10 8 cfu / g to about 3.3x10 4 cfu / g before feeding. Also, as shown in Fig. 7, the lactic acid bacteria group tended to increase from about 8.25x10 5 cfu / g to 3.75x10 7 cfu / g before feeding.
4) 이와 같이 본 발명에 따른 오미자 발효물의 사양시험에서 우수한 사양성적이 도출된 것은 in-vitro실험에서 나타난 면역증강 효능 및 항균 활성에 기인한 것으로 사료된다.
4) Thus, it was considered that the excellent specification results in the specification test of the fermented product of Omija according to the present invention were attributed to the immunostimulating effect and the antibacterial activity in the in-vitro experiment.
5. 5. 제조예Manufacturing example
(1) 사료 조성물(1) Feed composition
동물용 배합 사료에 상기 2.에서 제조된 오미자 발효물을 약 0.01~10 중량%의 양으로 혼합하여, 사료 조성물을 제조한 후, 펠렛화 및 과립화하였다.
The animal feed composition was mixed with about 0.01 to 10% by weight of the fermented Omija produced in the above 2. to prepare a feed composition, which was then pelletized and granulated.
(2) 주사제(2) Injection
상기 2.에서 제조된 오미자 발효물: 100 ㎎The Omija fermented product prepared in the above 2: 100 mg
소듐 메타비설파이트: 3.0 ㎎Sodium metabisulfite: 3.0 mg
메틸파라벤: 0.8 ㎎Methylparaben: 0.8 mg
프로필파라벤: 0.1 ㎎Propyl paraben 0.1 mg
주사용 멸균증류수: 적량Sterile sterilized distilled water for injection:
상기 성분을 혼합하고 통상의 방법으로 최종 부피가 2 ㎖가 되도록 제조하여, 앰플에 충전하고 멸균하여 주사제를 제조하였다.
The above ingredients were mixed and made into a final volume of 2 ml by a conventional method, filled in an ampoule and sterilized to prepare an injection.
(3) 정제(3) Purification
상기 2.에서 제조된 오미자 발효물: 200 ㎎The omelet fermented product prepared in the above 2: 200 mg
감자 전분: 100 ㎎Potato starch: 100 mg
락토오스: 100 ㎎Lactose: 100 mg
콜로이드성 규산: 16 ㎎Colloidal silicic acid: 16 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 정제 제조방법에 따라 상기 성분을 혼합하고 타정하고 정제를 제조하였다.
The ingredients were mixed and tableted according to a conventional tablet preparation method to prepare tablets.
(4) 캡슐제(4) Capsules
상기 2.에서 제조된 오미자 발효물: 100 ㎎The Omija fermented product prepared in the above 2: 100 mg
유당: 50 ㎎Lactose: 50 mg
전분: 50 ㎎Starch: 50 mg
탈크: 2 ㎎Talc: 2 mg
스테아린산 마그네슘: 적량Magnesium stearate:
통상의 캡슐 제조방법에 따라 상기 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.The above components were mixed according to a conventional capsule manufacturing method and filled in gelatin capsules to prepare capsules.
(5) 환제(5) pillars
상기 2.에서 제조된 오미자 발효물: 120 ㎎The Omija fermented product prepared in the above 2: 120 mg
옥수수 전분: 100 ㎎Corn starch: 100 mg
멸균 증류수: 적량Sterilized distilled water: suitable amount
상기 성분을 혼합하고, 통상의 환제 제조방법에 따라 적절한 크기를 갖는 구형으로 제환하여 환제를 제조하였다.
The above ingredients were mixed and pelletized to spheres of appropriate size according to conventional pellet manufacturing methods to produce pellets.
(6) 식품(6) Food
1) 각종 소스 및 양념류1) Various sauces and condiments
상기 2.에서 제조된 오미자 발효물 0.1~10.0 중량%을 각종 소스 및 양념에 첨가하여 오미자 발효물이 함유된 소스 및 양념류를 제조하였다.0.1 to 10.0% by weight of the Omija fermented product prepared in 2. above was added to various sauces and seasonings to prepare sauces and seasonings containing the omija fermented products.
2) 유제품 제조2) Manufacture of dairy products
상기 2.에서 제조된 오미자 발효물 5~10 중량%가 첨가된 우유를 이용하여 버터, 아이스크림과 같은 유제품을 제조하였다.Dairy products such as butter and ice cream were prepared using the milk to which 5 to 10% by weight of the fermented Omija prepared in 2 above was added.
3) 밀가루 식품의 제조3) Manufacture of flour food
상기 2.에서 제조된 오미자 발효물 0.5~5.0 중량%가 첨가된 밀가루를 이용하여 빵, 케이크, 쿠키 및 면류와 같은 식품을 제조하였다.Foods such as breads, cakes, cookies and noodles were prepared using wheat flour added with 0.5 to 5.0% by weight of the fermented Omija produced in 2 above.
4) 음료의 제조4) Manufacture of beverages
올리고당(2%), 액상과당(0.5%), 설탕(2%), 식염(0.5%), 물(75%) 등의 음료 재료에 상기 2.에서 제조된 오미자 발효물을 적량 혼합하여, 살균함으로써 음료를 제조하였다.
(2), liquid fructose (0.5%), sugar (2%), salt (0.5%) and water (75% To prepare a beverage.
상기 본 발명은 전술한 실시예 및 첨부된 도면에 의해 한정되는 것이 아니고, 본 발명의 기술적 사상을 벗어나지 않는 범위 내에서 여러 가지 치환, 변형 및 변경이 가능하다는 것이 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명백할 것이다.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the invention is not limited to the disclosed exemplary embodiments or constructions. Various changes, substitutions and alterations can be made hereto without departing from the spirit and scope of the invention. It will be clear to those who have knowledge.
Claims (19)
An Omija fermented product obtained by fermenting Omiza extract with L. plantarum VITA-L02 (KCTC 12030BP).
상기 L. plantarum VITA-L02(KCTC 12030BP)는 상기 오미자 추출물 중량에 대하여 0.001~15 중량%의 양으로 접종되는 것을 특징으로 하는
오미자 발효물.
The method according to claim 1,
Wherein said L. plantarum VITA-L02 (KCTC 12030BP) is inoculated in an amount of 0.001 to 15% by weight based on the weight of said Omiza extract
Fermented water.
상기 오미자 추출물은 열수추출, 메탄올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 형성된 것을 특징으로 하는
오미자 발효물.
The method according to claim 1,
Wherein the Omiza extract is formed by one or more methods selected from the group consisting of hot water extraction, methanol extraction and alcohol extraction
Fermented water.
상기 오미자 추출물은 30~100 중량%의 농도를 갖는 것을 특징으로 하는
오미자 발효물.
The method according to claim 1,
Wherein the Omiza extract has a concentration of 30 to 100% by weight
Fermented water.
상기 오미자 추출물은 일 이상의 탄소원 및 일 이상의 질소원을 더 포함하는 것을 특징으로 하며,
상기 탄소원은 글루코오스, 말토오스, 수크로오스, 프럭토오스, 만노오스, 락토오스, 크실로스, 갈락토오스, 옥수수 전분 및 가용성 전분으로 이루어진 군으로부터 선택되는 일 이상이며,
상기 질소원은 트립톤, 맥아 추출물, 질산칼륨, 황산암모늄, 염화암모늄, 질산암모늄, 카제인, 콩 단백질 및 효모 추출물로 이루어진 군으로부터 선택되는 일 이상인
오미자 발효물.
The method according to claim 1,
Wherein the Schizandra chinensis extract further comprises at least one carbon source and at least one nitrogen source,
Wherein the carbon source is at least one member selected from the group consisting of glucose, maltose, sucrose, fructose, mannose, lactose, xylose, galactose, corn starch and soluble starch,
Wherein the nitrogen source is at least one member selected from the group consisting of tryptone, malt extract, potassium nitrate, ammonium sulfate, ammonium chloride, ammonium nitrate, casein, soy protein and yeast extract
Fermented water.
상기 탄소원 및 질소원은 각각 오미자 추출물 중량에 대하여 1~20 중량%의 양으로 포함되는
오미자 발효물.
6. The method of claim 5,
The carbon source and the nitrogen source are contained in an amount of 1 to 20% by weight based on the weight of the Omija extract, respectively
Fermented water.
상기 오미자 추출물에 L. plantarum VITA-L02(KCTC 12030BP)을 접종하여 발효시키는 단계를 포함하는
오미자 발효물의 제조방법.
Extracting omiza to form an extract; And
The step of inoculating L. plantarum VITA-L02 (KCTC 12030BP) into the above-mentioned Omiza extract and fermenting
A method for producing a fermented product of Omija.
상기 추출물 형성 단계는,
열수추출, 메탄올 추출 및 주정 추출로 이루어진 군으로부터 선택되는 일 이상의 방법에 의하여 이루어지는 것을 특징으로 하는
오미자 발효물의 제조방법.
8. The method of claim 7,
Wherein the extracting step comprises:
Characterized in that it is made by one or more methods selected from the group consisting of hot water extraction, methanol extraction and alcohol extraction
A method for producing a fermented product of Omija.
상기 추출물 형성 단계는,
오미자에 증류수를 첨가하는 단계;
60~130℃의 온도에서 30~240분 동안 열수추출하는 단계; 및
여과하는 단계를 포함하는
오미자 발효물의 제조방법.9. The method of claim 8,
Wherein the extracting step comprises:
Adding distilled water to the ozonizer;
Hydrothermal extraction at a temperature of 60 to 130 DEG C for 30 to 240 minutes; And
Comprising filtering
A method for producing a fermented product of Omija.
상기 발효 단계는 25~37℃의 온도에서 6~60시간 동안 이루어지는 것을 특징으로 하는
오미자 발효물의 제조방법.
8. The method of claim 7,
Wherein the fermentation step is carried out at a temperature of 25 to 37 DEG C for 6 to 60 hours
A method for producing a fermented product of Omija.
상기 추출물 형성 단계 이후, 오미자 추출물의 농도를 30~100 중량%로 조절하는 단계를 더 포함하는
오미자 발효물의 제조방법.
8. The method of claim 7,
Further comprising, after the step of forming the extract, adjusting the concentration of the Omiza extract to 30 to 100% by weight
A method for producing a fermented product of Omija.
상기 L. plantarum VITA-L02(KCTC 12030BP)은 상기 오미자 추출물 중량에 대하여 0.001~15 중량%의 양으로 접종되는 것을 특징으로 하는
오미자 발효물의 제조방법.
8. The method of claim 7,
Wherein said L. plantarum VITA-L02 (KCTC 12030BP) is inoculated in an amount of 0.001 to 15% by weight based on the weight of said Omiza extract
A method for producing a fermented product of Omija.
A feed composition for enhancing immunity containing the fermented Omija product according to any one of claims 1 to 6.
A pharmaceutical composition for antibacterial and immunological enhancement containing the fermented Omija product according to any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120005809A KR101396842B1 (en) | 2012-01-18 | 2012-01-18 | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020120005809A KR101396842B1 (en) | 2012-01-18 | 2012-01-18 | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130084887A KR20130084887A (en) | 2013-07-26 |
| KR101396842B1 true KR101396842B1 (en) | 2014-05-19 |
Family
ID=48995323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020120005809A KR101396842B1 (en) | 2012-01-18 | 2012-01-18 | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101396842B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160013410A (en) * | 2014-07-25 | 2016-02-04 | 동의대학교 산학협력단 | prevent or improvement COMPOSITION INCLUDING Schisandra chinensis semen Extracts For vascular disease And Manufacturing Method thereof |
| KR102066821B1 (en) | 2019-09-06 | 2020-01-15 | 이훈 | Natural Complex Cosmetic Preservative Composition |
| KR20220136791A (en) | 2021-04-01 | 2022-10-11 | 한국시그니처(주) | Composition for enhancing immunity and antibacterial activity of livestock |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101616187B1 (en) | 2014-06-19 | 2016-04-29 | 계명대학교 산학협력단 | Method for manufacturing fermented beverage with Schisandra chinensis using GABA producing Lactobacillus |
| KR102471549B1 (en) * | 2020-12-23 | 2022-11-30 | 한두레축산 영농조합법인 | Method for breeding pig using schisandra chinesis composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100972116B1 (en) | 2009-10-29 | 2010-07-23 | (주)한국파비스 알엔디 | Method of producing fermentation of herbal medicine, the fermentation produced thereby, and food comprising the fermentation |
| KR20100101258A (en) * | 2009-03-09 | 2010-09-17 | 주식회사 엘씨에스바이오텍 | Methods for fermentation of natural plants or herbal medicines and fermented products using the same methods |
| KR20110108686A (en) * | 2010-03-29 | 2011-10-06 | 주식회사 케이씨아이 | Antioxidant containing extracts of natural materials and composition of feed, food or cosmetic |
-
2012
- 2012-01-18 KR KR1020120005809A patent/KR101396842B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100101258A (en) * | 2009-03-09 | 2010-09-17 | 주식회사 엘씨에스바이오텍 | Methods for fermentation of natural plants or herbal medicines and fermented products using the same methods |
| KR100972116B1 (en) | 2009-10-29 | 2010-07-23 | (주)한국파비스 알엔디 | Method of producing fermentation of herbal medicine, the fermentation produced thereby, and food comprising the fermentation |
| KR20110108686A (en) * | 2010-03-29 | 2011-10-06 | 주식회사 케이씨아이 | Antioxidant containing extracts of natural materials and composition of feed, food or cosmetic |
Non-Patent Citations (2)
| Title |
|---|
| 이주연 외. 한국식품과학회지. 2001년. 제33권 제3호, pp 389-394 * |
| 이주연 외. 한국식품과학회지. 2001년. 제33권 제3호, pp 389-394* |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160013410A (en) * | 2014-07-25 | 2016-02-04 | 동의대학교 산학협력단 | prevent or improvement COMPOSITION INCLUDING Schisandra chinensis semen Extracts For vascular disease And Manufacturing Method thereof |
| KR101720385B1 (en) * | 2014-07-25 | 2017-03-28 | 동의대학교 산학협력단 | prevent or improvement COMPOSITION INCLUDING Schisandra chinensis semen Extracts For vascular disease And Manufacturing Method thereof |
| KR102066821B1 (en) | 2019-09-06 | 2020-01-15 | 이훈 | Natural Complex Cosmetic Preservative Composition |
| KR20220136791A (en) | 2021-04-01 | 2022-10-11 | 한국시그니처(주) | Composition for enhancing immunity and antibacterial activity of livestock |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130084887A (en) | 2013-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101379404B1 (en) | Fermentation product of scutellaria baicalensis and antibacterial and immune enhancing composition comprising the same | |
| CN103893214B (en) | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder | |
| CN112501046B (en) | Lactobacillus fermentum with weight-losing function and application thereof | |
| CN110903995B (en) | Probiotic edible composition and food with digestion promoting effect | |
| CN110564638A (en) | Lactobacillus reuteri with probiotic characteristics and application thereof | |
| CN110495522B (en) | Traditional Chinese medicine microecological preparation for feed | |
| KR102543494B1 (en) | Novel probiotics and use thereof | |
| KR101396842B1 (en) | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same | |
| CN102618452B (en) | Preparation method, composition and application of lactobacillus salivarius and its metabolites | |
| CN115381860B (en) | Composition for protecting alcoholic liver injury and preparation method and application thereof | |
| CN116042470B (en) | Traditional Chinese medicine fermentation by using novel rhamnose cheese bacillus strain and application thereof | |
| CN115838676B (en) | Traditional Chinese medicine fermentation by using novel lactobacillus plantarum strain and application | |
| CN114908020B (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
| CN113913346A (en) | Lactobacillus paracasei JN-1 and application thereof | |
| CN111254088A (en) | Bacillus coagulans strain and application thereof | |
| CN106942484A (en) | One boar additive for microbe feedstuff and preparation method thereof | |
| CN1899314A (en) | Process for preparing lactic acid bacteria oral liquor | |
| CN114686405B (en) | Bifidobacterium bifidum with functions of reducing fat, relieving hyperglycemia and regulating intestinal immunity and application thereof | |
| CN114774315B (en) | Application of lactobacillus rhamnosus strain LRa05 in preparation of immunity enhancing product and/or eczema relieving product | |
| CN109207389B (en) | Thrombolytic lipid-lowering probiotic compound bacteria traditional Chinese medicine oral liquid and preparation method thereof | |
| CN115119940A (en) | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori | |
| CN111685255B (en) | Probiotic solid beverage for enhancing immune function and preparation method thereof | |
| CN108795823A (en) | It is a kind of improve women pregnant and lying-in women's intestinal flora probiotics cultural method and application | |
| KR102548488B1 (en) | A Novel Lactobacillus reuteri strain derived from Panax ginseng and the use thereof | |
| KR102501957B1 (en) | A novel Lactobacillus casei strain derived from Panax ginseng and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20170302 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20180320 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20190227 Year of fee payment: 6 |